Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct)
This research study, called AXL-SolidAct, is looking at a new treatment for people who have a moderate case of COVID-19. The treatment is a medicine called bemcentinib. Scientists want to find out if bemcentinib can help patients recover more quickly and stop their condition from getting worse. They will also carefully check for any side effects to make sure the medicine is safe. Some patients will receive bemcentinib, while others will receive a dummy pill (placebo) to fairly compare the effects. The study will mainly look at how patients' health changes over eight days, using a special scale to track their COVID-19 symptoms.
At a glance
What is this study about?
This study is trying to find new ways to treat people who have caught the COVID-19 virus, specifically those who have a moderate level of illness. You might be asked to join if your COVID-19 symptoms are not too mild, but also not yet severe enough to need intensive care. The main goal is to see if a new drug, called bemcentinib, can help people get better more quickly and stop them from needing more serious hospital care.
Researchers want to understand if this new medicine can make a real difference. They will carefully follow patients' health over time to see if the drug helps improve symptoms and prevents the disease from getting worse. They will also be checking very closely for any side effects the medicine might cause, making sure that patient safety is a top priority throughout the study.
To make sure the results are accurate, some patients will receive the actual medicine, bemcentinib, while others will receive a 'placebo'. A placebo looks exactly like the medicine but contains no active drug. This comparison helps the researchers know if any improvements are truly due to the medicine itself and not just other factors. Your health will be monitored using a special scale that tracks how COVID-19 affects your body over about a month.
Key takeaways
- This study is testing a new medicine for moderate COVID-19.
- It aims to see if the medicine helps people get better faster and prevents worsening.
- Some people will get the active medicine, others a dummy pill (placebo).
- Safety is a top priority, and side effects will be closely watched.
- The study lasts for up to 90 days, with main checks around 8 to 29 days.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This study is looking for adults who are aged 18 or older. Both men and women are welcome to take part.
To be considered, you must have been diagnosed with COVID-19, and your illness should be considered 'moderate' by the study doctors. This means your symptoms are not too mild, but you are also not in a critical condition needing intensive care.
There might be other specific health requirements or conditions that mean you can or cannot join the study. These will be discussed in detail with the study team if you are interested in taking part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with COVID-19?
- Is your COVID-19 illness considered 'moderate' by a doctor?
- Are you able to attend regular study appointments?
- Are you willing to potentially receive a dummy pill instead of the study medicine?
What does participation involve?
If you decide to join this study, you will either receive the active study medicine (bemcentinib) or a dummy pill (placebo), given as capsules. Neither you nor your doctor will know which you are receiving. You will have regular visits with the study team, likely at a hospital or clinic, where you will be assessed. These assessments will involve checking your symptoms, taking blood samples, and possibly swabs to check for the virus. The main health check will happen around Day 8 after you start treatment, with further checks at Day 15 and Day 29. The study team will also monitor if your health gets worse or if you need to go into hospital. You'll also be asked to answer questions about how you feel after 90 days. The total time you will be closely followed in the study could be up to 90 days or even longer for some safety checks, and you will be asked about your health for up to two months after starting the treatment.
Potential risks and benefits
Locations (10)
- —UnverifiedGreece
- —UnverifiedLuxembourg
- —UnverifiedCzechia
- —UnverifiedIreland
- —UnverifiedFrance
- —UnverifiedSlovakia
- —UnverifiedBelgium
- —UnverifiedNorway
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is COVID-19 'moderate' illness?
Moderate COVID-19 means your symptoms are not mild, but you are also not in a severe condition requiring intensive hospital care.
What is a 'placebo'?
A placebo is a dummy pill that looks exactly like the real medicine but does not contain any active drug. It helps researchers fairly test the medicine.
Will I know if I'm getting the real medicine?
No, both you and your study doctor won't know if you're receiving the real medicine or the placebo. This is called 'blinding' and helps keep the study fair.
How long will I be in the study?
You'll be closely monitored for about a month, but your health will be checked for up to 90 days, and even up to two months for some safety information.
Can I stop participating if I want to?
Yes, you can leave the study at any time, for any reason. It will not affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.